Personalized azacitidine combinations for breast or stomach cancer
Part of Cancer, Digestive system, Skin clinical trials.
This Phase 1/2 trial tests different combinations that include azacitidine, chosen based on your tumor’s lab “response markers” and past drug-sensitivity screening. It aims to find safer dosing and see whether these personalized combinations can shrink solid tumors such as breast or stomach cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re age 21 or older, and able to do daily activities fairly well (ECOG 0–2).
- Your latest blood tests (within 21 days before treatment) must meet safe levels: neutrophils and platelets are high enough.
- Your kidneys and liver blood tests must be within allowed limits (kidney function ≥30 mL/min, and liver enzymes/bilirubin not too high).
- You have breast or gastric (stomach) cancer, and your care team is considering palliative treatment with docetaxel, paclitaxel, or irinotecan.
- You must have completed the trial’s earlier drug-screening test (QPOP/QGAIN or NGAIN results) showing possible benefit from combining azacitidine with a taxane (docetaxel/paclitaxel) or irinotecan.
- Your tumor markers are “raised” on local lab tests (for example CEA/CA19-9 or CA-15-3/CA-125/AFP, plus certain methylation markers like DNMT).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs (5-Azacitidine and a PD-1/PD-L1 inhibitor) for people whose solid tumors stopped responding to standard PD-1/PD-L1 immunotherapy alone. The goal is to see if this new combination can help shrink the tumor or slow its growth.
This trial studies whether giving a low dose of azacitidine before surgery can shrink or control high-risk early breast cancer. It’s meant for adults whose cancer has not yet spread to distant organs.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This trial tests a combination of two drugs, nab-paclitaxel and cadonilimab, as a second treatment for advanced stomach cancer that has spread to the belly lining. It may be an option if you haven't had any prior cancer therapy.
This study tests a combination of two drugs (paclitaxel, a chemotherapy, and apatinib, a targeted drug) with an immunotherapy (adebrelimab) for advanced stomach cancer. It may be an option if you've already tried immunotherapy and need a new approach.
This trial tests whether adding a special type of chemotherapy sprayed directly into the abdomen (PIPAC) to standard chemotherapy is safer and works better for stomach cancer that has spread only to the lining of the abdomen.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.